Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
Oncology Reports|December 18, 2010
Association of the transforming growth factor ß1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancerYosuke Togashi, Katsuhiro Masago, Shiro Fujita, et al.
Clinical Lung Cancer|January 29, 2011
Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapyKatsuhiro Masago, Shiro Fujita, Yosuke Togashi, et al.
Lung Cancer (Amsterdam, Netherlands)|March 8, 2011
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancerYosuke Togashi, Katsuhiro Masago, Shiro Fujita, et al.
Cancer|October 2, 2010
Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinomaYosuke Togashi, Katsuhiro Masago, Takeshi Kubo, et al.
BMC Medical Genetics|December 1, 2010
Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapyShiro Fujita, Katsuhiro Masago, Yukimasa Hatachi, et al.
Medical Oncology (Northwood, London, England)|March 20, 2010
Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancerKatsuhiro Masago, Shiro Fujita, Tadashi Mio, et al.
Cancer Science|July 15, 2009
Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancerKatsuhiro Masago, Shiro Fujita, Yung Haku Kim, et al.
Medical Oncology (Northwood, London, England)|December 8, 2010
Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitorKaoru Irisa, Katsuhiro Masago, Yosuke Togashi, et al.
Anticancer Research|May 13, 2015
A new strategy for metachronous primary lung cancer: stereotactic body radiation therapy with concurrent chemotherapyJumpei Takeshita, Katsuhiro Masago, Ryoji Kato, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancerAkito Hata, Nobuyuki Katakami, Shigeki Nanjo, et al.
Pageof 13